Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy (Q24241680)

Europe PubMed Central

title

Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy (English)

0 references

0 references

0 references

1 reference

5

0 references

Andreas Engert

7

0 references

Ina Monsef

4

0 references

Frauke Naumann

2

object named as

Frauke Naumann

0 references

Christine Herbst

1

object named as

Christine Herbst

0 references

author name string

Eva-Brigitta Kruse

3

0 references

Holger Schulz

Cochrane Database of Systematic Reviews

6

0 references

publication date

21 January 2009

0 references

published in

0 references

cites work

Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Human Granulocyte Colony-Stimulating Factor in Children With High-Risk Acute Lymphoblastic Leukemia: A Children’s Cancer Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Infection in cancer patients. A continuing association

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

The case of the misleading funnel plot

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Systematic reviews and meta-analysis of febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Fever in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Superinfections by Escherichia coli resistant to fluoroquinolones in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

The biology of GM-CSF: regulation of production and interaction with its receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

7 January 2021

Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

7 January 2021

Administration of recombinant human granulocyte-macrophage colony-stimulating factor to children undergoing allogeneic marrow transplantation: a prospective, randomized, double-masked, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

7 January 2021

A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

7 January 2021

Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

7 January 2021

Assessment of the value of treatment with granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

7 January 2021

Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

7 January 2021

Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

7 January 2021

Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

7 January 2021

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

7 January 2021

Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007107.PUB2

7 January 2021